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BACKGROUND
Studies in animals and in humans have suggested that docosahexaenoic acid (DHA), an 
n−3 long-chain polyunsaturated fatty acid, might reduce the risk of bronchopulmonary 
dysplasia, but appropriately designed trials are lacking.
METHODS
We randomly assigned 1273 infants born before 29 weeks of gestation (stratified accord-
ing to sex, gestational age [<27 weeks or 27 to <29 weeks], and center) within 3 days 
after their first enteral feeding to receive either an enteral emulsion providing DHA at a 
dose of 60 mg per kilogram of body weight per day or a control (soy) emulsion without 
DHA until 36 weeks of postmenstrual age. The primary outcome was bronchopulmo-
nary dysplasia, defined on a physiological basis (with the use of oxygen-saturation 
monitoring in selected infants), at 36 weeks of postmenstrual age or discharge home, 
whichever occurred first.
RESULTS
A total of 1205 infants survived to the primary outcome assessment. Of the 592 infants 
assigned to the DHA group, 291 (49.1% by multiple imputation) were classified as having 
physiological bronchopulmonary dysplasia, as compared with 269 (43.9%) of the 613 in-
fants assigned to the control group (relative risk adjusted for randomization strata, 1.13; 
95% confidence interval [CI], 1.02 to 1.25; P = 0.02). The composite outcome of physiolog-
ical bronchopulmonary dysplasia or death before 36 weeks of postmenstrual age occurred 
in 52.3% of the infants in the DHA group and in 46.4% of the infants in the control group 
(adjusted relative risk, 1.11; 95% CI, 1.00 to 1.23; P = 0.045). There were no significant dif-
ferences between the two groups in the rates of death or any other neonatal illnesses. 
Bronchopulmonary dysplasia based on a clinical definition occurred in 53.2% of the 
infants in the DHA group and in 49.7% of the infants in the control group (P = 0.06).
CONCLUSIONS
Enteral DHA supplementation at a dose of 60 mg per kilogram per day did not result in a 
lower risk of physiological bronchopulmonary dysplasia than a control emulsion among 
preterm infants born before 29 weeks of gestation and may have resulted in a greater risk. 
(Funded by the Australian National Health and Medical Research Council and others; 
Australian New Zealand Clinical Trials Registry number, ACTRN12612000503820.)
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Bronchopulmonary dysplasia is a se-rious complication of preterm birth. It is characterized by an inflammatory process 
causing abnormal lung development, decreased 
vascular and alveolar development,1 and the need 
for supplemental oxygen or assisted ventilation 
at 36 weeks of postmenstrual age (gestational 
age [weeks between the first day of the last men-
strual period and birth] plus chronological age 
[weeks elapsed after birth]).2 Bronchopulmonary 
dysplasia is associated with long-term pulmonary 
and neurodevelopmental impairment and increased 
needs for health and education services.3,4
Some evidence has suggested that the n−3 
long-chain polyunsaturated fatty acid docosa-
hexaenoic acid (DHA) may help protect against 
the development of bronchopulmonary dysplasia. 
Enriching diets with DHA can change the inflam-
matory balance, modulating cell function and 
suppressing inflammatory responses.5,6 Among 
prespecified secondary outcomes in our previous 
randomized, controlled trial, which was designed 
to assess the effect of DHA on developmental 
outcomes,7 we observed a lower incidence of 
bronchopulmonary dysplasia with a DHA-supple-
mented diet than with a control diet in the sub-
group of infants who had a birth weight of less 
than 1250 g (P = 0.04).8 Observational data from 
infants born before 30 weeks of gestation show 
an association between low blood levels of DHA 
and bronchopulmonary dysplasia.9 In addition, 
studies in animals have shown reduced inflam-
matory responses, improved lung growth, and 
increased production of pulmonary surfactant 
with DHA supplementation.10-14 In preterm infants, 
direct enteral DHA supplementation from the 
onset of feeding is associated with an acceptable 
side-effect profile and inhibits the early decline 
in DHA levels that is typically seen during the 
transition to full enteral feeding.15 We conducted 
this randomized trial to determine the effect of 
DHA supplementation on the incidence of bron-
chopulmonary dysplasia among infants born be-
fore 29 weeks of gestation.
Me thods
Trial Design and Oversight
The N−3 Fatty Acids for Improvement in Respi-
ratory Outcomes (N3RO) trial, designed and con-
ducted by the authors, was a randomized, blind-
ed, controlled trial that was conducted at 13 
centers in Australia, New Zealand, and Singa-
pore. The human research ethics committee re-
sponsible for each participating center approved 
the trial protocol16 (available with the full text of 
this article at NEJM.org), and appropriate regula-
tory approvals were obtained. (For details, see the 
Supplementary Appendix, available at NEJM.org.) 
The protocol was peer reviewed by the IMPACT 
Clinical Trials Network for Mothers’ and Babies’ 
Health. An independent serious-adverse-event com-
mittee evaluated deaths. An independent trial 
monitoring committee reviewed trial safety and 
progress. The committee had access to key trial 
outcomes according to group, including the pri-
mary outcome. No formal interim analysis of ef-
ficacy was planned or undertaken; the committee 
performed two reviews of safety and recom-
mended that the trial continue. The Australian 
National Health and Medical Research Council 
funded the trial, and Clover (Westmeadows, VIC, 
Australia) donated the trial product; these enti-
ties had no role in the design or conduct of the 
trial; the collection, analysis, or interpretation of 
the data; the writing, review, or approval of the 
manuscript; or the decision to submit the manu-
script for publication. The first four authors and 
the last author had full access to all the data and 
vouch for the completeness and accuracy of the 
data. All the authors vouch for the fidelity of the 
trial to the protocol.
Participants
Infants born before 29 weeks of gestation who 
had commenced enteral feeding in the previous 
3 days were eligible to participate. Infants were 
ineligible if they had a major congenital or chro-
mosomal abnormality, were participating in an-
other trial of fatty-acid supplementation, or were 
receiving intravenous lipids containing fish oil 
or if the mother wanted to provide breast milk 
and take supplements containing DHA at a dose 
of more than 250 mg per day.
Randomization and Blinding
A computer-generated randomization schedule 
that used balanced variable blocks of 2, 4, and 
6 in a ratio of 1:2:1 was prepared by an indepen-
dent statistician. Randomization was stratified 
according to sex, gestational age (<27 completed 
weeks or 27 to <29 weeks), and center. Infants 
from multiple births underwent randomization 
individually. Research nurses assessed infants 
for eligibility and invited the parents or guardians 
of eligible infants to enter their infant in the 
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trial. After written informed consent was ob-
tained, infants were randomly assigned with the 
use of our Web-based randomization service. A 
unique trial identification number was assigned 
to each infant, and a unique product identifica-
tion number identified the trial emulsion con-
taining the intervention or control emulsion, pre-
packed according to the randomization schedule. 
Participants, their families, and clinical and re-
search personnel were unaware of the random-
ization assignments. The intervention and con-
trol emulsions were identical in viscosity, color, 
packaging, and labeling.
Trial Intervention
Both the DHA emulsion and the soy emulsion 
were emulsified with 1% lecithin and contained 
20% total fat and 6% protein. The DHA emul-
sion comprised a microencapsulated aqueous 
emulsion of fractionated tuna oil (70% of total 
oil as DHA in triglyceride form); 0.5 ml of the 
DHA emulsion contained 60 mg of DHA, 4 mg of 
eicosapentaenoic acid, 4.6 mg of vitamin C, and 
0.05 mg of vitamin E. For the control emulsion, 
0.5 ml contained 55 mg of linoleic acid, 5.7 mg 
of alpha-linolenic acid, 4.8 mg of vitamin C, and 
0.01 mg of vitamin E.
The emulsions were administered enterally, at a 
dose of 0.17 ml per kilogram of body weight three 
times daily (total, 0.5 ml per kilogram per day). 
Thus, infants in the DHA group received 60 mg 
of DHA per kilogram per day, and those in the 
control group received no additional DHA. The 
treatment dose provided sufficient DHA to match 
the estimated fetal accretion rate during the last 
trimester.17 The dose calculation was adjusted 
weekly for changes in body weight. The trial 
emulsions were given immediately before a feed-
ing through a nasogastric or orogastric tube; if 
feedings were stopped, the emulsion was with-
held and was recommenced as soon as feedings 
restarted. The trial emulsion was continued until 
the primary outcome assessment. The emulsion 
met quality thresholds throughout and beyond 
the stated product shelf life.18 Apart from the 
administration of the trial emulsion, clinical 
management was under the direction of neona-
tologists according to local protocols. The use of 
intravenous lipid emulsions containing fish oil 
for the treatment of liver disease associated with 
parenteral nutrition was at the discretion of the 
attending neonatologist, with the trial emul-
sions continued when enteral feedings occurred.
Outcomes
The primary outcome was the incidence of physi-
ological bronchopulmonary dysplasia (assessed 
at 36 weeks of postmenstrual age or discharge 
home, whichever occurred first), as determined 
on the basis of requirements for supplemental 
oxygen or respiratory support with an assessment 
of oxygen saturation.16,19 Secondary respiratory 
outcomes included the composite of physiologi-
cal bronchopulmonary dysplasia or death before 
36 weeks of postmenstrual age, clinical broncho-
pulmonary dysplasia (defined by clinical manage-
ment with supplemental oxygen or respiratory 
support at the time of the primary outcome as-
sessment), severity of bronchopulmonary dyspla-
sia (according to National Institute of Child 
Health and Human Development [NICHD] defi-
nitions2,19), and the requirement for respiratory 
support. Other secondary outcomes included 
retinopathy of prematurity, intraventricular hem-
orrhage, sepsis, necrotizing enterocolitis, and 
measures of safety and tolerance (death before 
36 weeks of postmenstrual age and during the 
first hospitalization, length of hospital stay, feed-
ing tolerance [number of days to reach full 
enteral feeding and number of days on which 
one or more feedings were stopped], and growth). 
(For definitions of outcomes, see the Supplemen-
tary Appendix.) All the infants were followed to 
the expected date of delivery or first discharge 
home, whichever occurred first. A whole-blood 
specimen (30 μl) was obtained at randomization 
and at the primary outcome assessment for fatty-
acid analysis.20
Statistical Analysis
On the basis of an estimated incidence of bron-
chopulmonary dysplasia among infants born be-
fore 29 weeks of gestation of 51.4%,7 we calcu-
lated that 1244 infants (622 per group) would 
need to be enrolled for the trial to have 90% 
power to detect an absolute difference of 10 per-
centage points and a relative difference of 19% 
between trial groups in the incidence of broncho-
pulmonary dysplasia at 36 weeks of postmen-
strual age, at a two-tailed alpha level of 0.05. The 
sample accounts for a variance inflation factor 
of 15% (11% multiple births and 4% death rate 
before 36 weeks of postmenstrual age, as esti-
mated from our previous trial7). Analyses were 
performed on an intention-to-treat basis accord-
ing to a prespecified statistical analysis plan. The 
incidence of bronchopulmonary dysplasia was 
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compared between groups with the use of a log-
binomial regression model, with a generalized 
estimating equation used to account for cluster-
ing of outcomes due to multiple births. Adjustment 
was made for randomization strata. Secondary 
analyses used log-binomial, linear, and negative-
binomial regression models with generalized 
estimating equations for binary, continuous, and 
count outcomes, respectively.
Missing data (excluding deaths) on physiologi-
cal bronchopulmonary dysplasia, mild broncho-
pulmonary dysplasia, moderate bronchopulmonary 
dysplasia, days on which one or more feedings 
were stopped, and growth were multiply imput-
ed according to treatment group with the use of 
chained equations. (For further details, see the 
Supplementary Appendix.) Multiple imputation 
was not applied for other outcomes, given the 
completeness of data (<1% missing data).
In planned subgroup analyses (76 total), we 
examined the effect of DHA supplementation 
according to the randomization strata of sex and 
gestational age; up to four significant interac-
tion tests (P<0.05) were expected owing to chance 
alone. All analyses were performed with the use 
of SAS software, version 9.3 (SAS Institute), with 
blinding to treatment group.
R esult s
Trial Participants
From June 18, 2012, to September 30, 2015, a 
total of 1098 women with 1273 infants under-
went randomization; 631 infants were assigned 
to receive the DHA emulsion and 642 to receive 
the control emulsion (Fig. 1). (For the number of 
infants recruited at each center, see the Supple-
mentary Appendix.) One infant in the DHA group 
was determined after randomization to have been 
born after 29 weeks of gestation and remained 
in the intention-to-treat analysis. Primary out-
come data were available for 1149 infants (90.3%); 
68 infants (5.3%) died before 36 weeks of post-
menstrual age and 56 (4.4%) were missing data 
on the primary outcome (Fig. 1). After imputa-
tion (excluding deaths), 1205 infants (592 in the 
DHA group and 613 in the control group) were 
included in the primary outcome analysis.
The baseline characteristics of the infants 
and their mothers were similar in the two treat-
ment groups (Table 1, and Table S1 in the Supple-
mentary Appendix). A mean of 90% of ordered 
doses was given overall in each group. In the 
first week after randomization, adherence was 
lowest, because the trial emulsion could be giv-
en only with a feeding (mean [±SD] percentage 
of doses given, 68±25% in the DHA group and 
69±25% in the control group). The baseline level 
of DHA in whole blood was 2.7±0.9% of total 
fatty acids in each group (Table 1). At the time 
of the primary outcome assessment (36.1±0.3 
weeks of postmenstrual age in each group), the 
DHA level was 3.9±0.7% of total fatty acids in 
the DHA group and 2.5±0.6% of total fatty acids 
in the control group (P<0.001); additional results 
with respect to fatty-acid levels in infants are 
presented in Tables S1, S2, and S3 in the Supple-
mentary Appendix. Overall, 59 infants received 
intravenous lipids containing fish oil (Table S4 
in the Supplementary Appendix).
Primary Outcome
Physiological bronchopulmonary dysplasia at 36 
weeks of postmenstrual age or discharge home, 
whichever occurred first, occurred in 291 of 592 
infants (49.1% by multiple imputation) in the 
DHA group and 269 of 613 infants (43.9%) in 
the control group (Table 2). The unadjusted rela-
tive risk was 1.12 (95% confidence interval [CI], 
0.99 to 1.26; P = 0.07); the adjusted relative risk 
was 1.13 (95% CI, 1.02 to 1.25; P = 0.02).
Secondary Outcomes
The composite outcome of physiological broncho-
pulmonary dysplasia or death before 36 weeks of 
postmenstrual age occurred in 52.3% of the in-
fants in the DHA group and 46.4% of the infants 
in the control group (adjusted relative risk, 1.11; 
95% CI, 1.00 to 1.23; P = 0.045) (Table 2). The 
incidence of clinical bronchopulmonary dyspla-
sia was 53.2% and 49.7%, respectively (adjusted 
relative risk, 1.09; 95% CI, 1.00 to 1.18; P = 0.06). 
The incidence of mild bronchopulmonary dys-
plasia was significantly lower in the DHA group 
than in the control group, but there were no sig-
nificant between-group differences in moderate 
or severe bronchopulmonary dysplasia (Table 2). 
There were no significant differences between 
Figure 1 (facing page). Screening, Randomization,  
and Follow-up.
DHA denotes docosahexaenoic acid.
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2024 Were eligible
1273 Underwent randomization
2254 Infants were assessed for eligibility
230 Were ineligible
40 Had congenital abnormalities
85 Had first enteral feeding >3 days earlier
2 Had gestational age >29 wk
59 Had no legally acceptable representative 
37 Had mothers who wanted to provide breast
milk and take supplements containing
>250 mg of DHA per day
7 Were receiving intravenous lipid emulsions
containing fish oil as early lipid parenteral
nutrition support
751 Did not undergo randomization 
53 Had parents or guardians who were not
approached
606 Had parents or guardians who declined
to participate
92 Died
631 Were assigned to the DHA group 642 Were assigned to the control group
9 Did not commence
treatment 
7 Died
1 Had parent or guardian
who withdrew consent
1 Had other reason
7 Died and had not
commenced treatment
8 Discontinued treatment
5 Had parent or guardian
who withdrew consent 
3 Had other reason
6 Discontinued treatment
2 Had parent or guardian
who withdrew consent 
4 Had other reason
592 Were included in primary analysis
(includes multiple imputation for
31 infants with missing data; multiple
imputation excluded deaths before 36 wk
of postmenstrual age)
613 Were included in primary analysis
(includes multiple imputation for
25 infants with missing data; multiple
imputation excluded deaths before 36 wk
of postmenstrual age)
561 Had data for analysis of primary
outcome
70 Did not have data for analysis
of primary outcome
39 Died before 36 wk of postmenstrual age
12 Did not undergo physiological
challenge
19 Did not undergo oximetric assessment
while breathing ambient air
588 Had data for analysis of primary
outcome
54 Did not have data for analysis
of primary outcome
29 Died before 36 wk of postmenstrual age
1 Had parent or guardian who with-
drew consent to collect outcome data
9 Did not undergo physiological challenge
15 Did not undergo oximetric assessment
while breathing ambient air
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Characteristic
DHA Group 
(N = 631)
Control Group 
(N = 642)
Mothers†
Age — yr‡ 30.5±5.7 30.4±5.9
Race or ethnic group — no./total no. (%)§
Australian Aboriginal, Torres Strait Islander, New Zealand Maori, or Native 
American
74/613 (12.1) 66/617 (10.7)
Asian 148/613 (24.1) 133/617 (21.6)
White 374/613 (61.0) 385/617 (62.4)
Black or Pacific Islander 17/613 (2.8) 33/617 (5.3)
Fish oil n−3 long‑chain polyunsaturated fatty‑acid supplements during pregnancy 
— no./total no. (%)
120/597 (20.1) 130/619 (21.0)
Smoked cigarettes during pregnancy — no./total no. (%) 107/608 (17.6) 104/619 (16.8)
Exposure to antenatal glucocorticoids — no./total no. (%) 586/631 (92.9) 592/641 (92.4)
Cesarean delivery — no. (%) 373 (59.1) 373 (58.1)
Histopathological evidence of chorioamnionitis or funisitis — no./total no. (%) 211/595 (35.5) 211/597 (35.3)
Infants
Female sex — no. (%) 293 (46.4) 300 (46.7)
Gestational age <27 wk — no. (%) 322 (51.0) 317 (49.4)
Gestational age — wk 26.7±1.5 26.7±1.5
Singleton birth — no. (%) 450 (71.3) 461 (71.8)
Birth weight — g 913±236 924±239
Apgar score at 5 minutes — median (IQR)¶ 8.0 (7.0–9.0) 8.0 (6.0–9.0)
Intubated in the delivery room — no./total no. (%) 386/630 (61.3) 388/642 (60.4)
Age at randomization — days
Median 3.0 3.0
IQR 2.0–4.0 2.0–4.0
Age at first enteral feeding — days
Median 2.0 2.0
IQR 1.0–3.0 1.0–3.0
DHA level in whole blood at randomization — % of total fatty acids‖ 2.7±0.9 2.7±0.9
Age at first dose of trial emulsion — days**
Median 4.0 4.0
IQR 3.0–5.0 3.0–5.0
*  Plus–minus values are means ±SD. There were no significant differences (P≥0.05) between the docosahexaenoic acid 
(DHA) group and control group for baseline variables. IQR denotes interquartile range.
†  Maternal characteristics have been summarized at the infant level (i.e., women were counted multiple times if they had 
multiple infants).
‡  Data were available for 626 mothers in the DHA group and 639 mothers in the control group.
§  Race and ethnic group were reported by the participants.
¶  Data were available for 629 infants in the DHA group and 637 infants in the control group.
‖  Data were available for 626 infants in the DHA group and 635 infants in the control group.
**  Data were available for 622 infants in the DHA group and 635 infants in the control group.
Table 1. Baseline Characteristics of the Infants and Their Mothers.*
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groups in the duration of respiratory support un-
til the assessment of the primary outcome, post-
natal glucocorticoid use, days receiving caffeine 
for lung disease, or days receiving diuretics for 
lung disease (Table 2).
There was no significant between-group dif-
ference in the risk of death before 36 weeks of 
postmenstrual age (6.2% in the DHA group and 
4.5% in the control group; adjusted relative risk, 
1.33; 95% CI, 0.84 to 2.12; P = 0.23) or in the 
percentage of infants who died before the first 
discharge home (7.9% in the DHA group and 
5.9% in the control group; adjusted relative risk, 
1.31; 95% CI, 0.88 to 1.96; P = 0.19) (Table 3). Nine 
deaths in the DHA group and eight in the con-
trol group were classified by the serious-adverse-
event committee as resulting from bronchopul-
monary dysplasia. There were no significant 
differences between groups in the frequency of 
any major clinical outcome, including sepsis, 
retinopathy of prematurity, necrotizing entero-
colitis, or intraventricular hemorrhage (Table 3, 
and Table S5 in the Supplementary Appendix). 
The number of days to reach full enteral feeding, 
the number of days on which one or more feed-
ings were stopped, and the length of hospital 
stay were similar in the two groups (Table 3). 
The z scores for weight, length, and head cir-
cumference also did not differ significantly 
between groups at the time of the primary 
outcome assessment or at the expected date 
of delivery or discharge home, whichever oc-
curred first (Table S6 in the Supplementary 
Appendix).
Outcome
DHA Group 
(N = 592)
Control Group 
(N = 613)
Adjusted Effect  
(95% CI)
Adjusted 
P Value
Physiological BPD: primary outcome — no. (%)† 291 (49.1) 269 (43.9) 1.13 (1.02–1.25) 0.02
Physiological BPD or death before 36 wk of postmenstrual age  
— no./total no. (%)†‡
330/631 (52.3) 298/642 (46.4) 1.11 (1.00–1.23) 0.045
Clinical BPD — no./total no. (%) 315/592 (53.2) 304/612 (49.7) 1.09 (1.00–1.18) 0.06
Severity of BPD
Mild — no. (%)†§ 80 (13.5) 108 (17.6) 0.76 (0.58–0.99) 0.04
Moderate — no. (%)†§ 65 (11.0) 50 (8.1) 1.35 (0.95–1.92) 0.10
Severe — no./total no. (%)¶ 202/592 (34.1) 194/612 (31.7) 1.07 (0.93–1.22) 0.36
Surfactant use — no./total no. (%)‡‖ 533/631 (84.5) 516/642 (80.4) 1.05 (1.00–1.10) 0.06
Days of respiratory support** 41.5±28.7 40.4±27.7 1.02 (0.94–1.10) 0.63
Postnatal glucocorticoids — no./total no. (%) 128/604 (21.2) 132/622 (21.2) 0.98 (0.80–1.19) 0.81
Days of caffeine use†† 61.9±19.3 60.7±18.9 1.01 (0.99–1.04) 0.29
Days of diuretic use†† 4.5±13.2 5.2±13.7 0.70 (0.46–1.07) 0.10
*  Denominators exclude deaths before 36 weeks of postmenstrual age unless otherwise indicated. The relative risk or ratio of means (DHA 
group vs. control group) is reported as the effect. Values were adjusted for randomization strata: sex, gestational age (<27 weeks or 27 to 
<29 weeks), and center. Physiological bronchopulmonary dysplasia was determined on the basis of requirements for supplemental oxygen 
or respiratory support with an assessment of oxygen saturation. Clinical bronchopulmonary dysplasia was defined by clinical management 
with supplemental oxygen or respiratory support at the time of the primary outcome assessment.
†  Missing data, excluding deaths, were multiply imputed. Average numerators across the 100 imputed data sets were rounded to the nearest 
integer value and hence may not correspond exactly with reported percentages.
‡  Denominators include deaths before 36 weeks of postmenstrual age.
§  The relative risk and P value were adjusted for country instead of center owing to the small number of events (<5) at some centers.
¶  Multiple imputation was not applied for severe bronchopulmonary dysplasia, given the completeness of data (<1% missing data).
‖  Data are for any surfactant given, before or after randomization.
**  Shown are days of respiratory support until the assessment of the primary outcome at 36 weeks of postmenstrual age or discharge home, 
whichever occurred first. Data were available for 592 infants in the DHA group and 611 infants in the control group.
††  Data were available for 587 infants in the DHA group and 610 infants in the control group.
Table 2. Primary Outcome and Secondary Respiratory-Related Outcomes.*
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on July 5, 2017. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
n engl j med 376;13 nejm.org March 30, 20171252
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Subgroup Analyses According to 
Randomization Strata
Primary and secondary outcomes stratified ac-
cording to sex and gestational-age category are 
presented in Tables S7 through S10 in the Sup-
plementary Appendix. There was no evidence 
of effect modification according to sex or gesta-
tional-age category for any outcome except days 
of diuretic use (P = 0.02 for interaction for both 
sex and gestational-age category); this finding 
should be interpreted with caution given the 
large number of interaction tests performed.
Discussion
In this multicenter, randomized, controlled trial, 
an enteral emulsion providing 60 mg of DHA per 
kilogram per day was not associated with a 
lower incidence of bronchopulmonary dysplasia 
(according to a physiological definition) than a 
control (soy) emulsion. The percentage of infants 
in whom bronchopulmonary dysplasia (defined 
physiologically) developed was higher with DHA 
supplementation than without supplementation 
(49.1% vs. 43.9%). When bronchopulmonary dys-
plasia was classified clinically according to the 
use of supplemental oxygen or respiratory sup-
port or limited to moderate or severe broncho-
pulmonary dysplasia, differences between groups 
were not significant.
The higher risk of the composite of physio-
logical bronchopulmonary dysplasia or death be-
fore 36 weeks of postmenstrual age in the DHA 
group than in the control group was driven by 
the higher risk of bronchopulmonary dysplasia 
in the DHA group; the risk of death did not dif-
Outcome
DHA Group 
(N = 631)
Control Group 
(N = 642)
Adjusted Effect 
 (95% CI)
Adjusted  
P Value
Death before 36 wk of postmenstrual age — no. (%) 39 (6.2) 29 (4.5) 1.33 (0.84–2.12) 0.23
Death — no. (%) 50 (7.9) 38 (5.9) 1.31 (0.88–1.96) 0.19
Any intraventricular hemorrhage — no. (%) 207 (32.8) 184 (28.7) 1.11 (0.95–1.31) 0.19
Grade 3 or 4 intraventricular hemorrhage — no. (%) 44 (7.0) 33 (5.1) 1.32 (0.87–2.03) 0.20
Periventricular leukomalacia — no./total no. (%)† 8/592 (1.4) 8/612 (1.3) 1.01 (0.39–2.64) 0.98
Porencephalic cysts — no./total no. (%)† 7/592 (1.2) 10/612 (1.6) 0.71 (0.27–1.84) 0.48
Retinopathy of prematurity — no./total no. (%)†
Unilateral, grade ≥3 15/589 (2.5) 12/612 (2.0) 1.29 (0.61–2.71) 0.51
Bilateral, grade ≥3 47/589 (8.0) 51/612 (8.3) 0.93 (0.64–1.33) 0.68
Requiring therapy 33/589 (5.6) 35/612 (5.7) 0.96 (0.61–1.50) 0.85
Sepsis — no./total no. (%)† 160/611 (26.2) 182/623 (29.2) 0.89 (0.76–1.05) 0.16
Necrotizing enterocolitis — no./total no. (%)† ‡ 50/601 (8.3) 44/619 (7.1) 1.16 (0.79–1.69) 0.46
Days to reach full enteral feeding§ 17.8±20.1 17.9±13.3 0.99 (0.91–1.08) 0.78
No. of days on which ≥1 feeding was stopped¶ 7.2±8.4 7.3±9.4 1.00 (0.87–1.14) 0.95
Length of hospital stay — days‖
Median 91 87 0.91 (0.81–1.02) 0.09
IQR 72–112 71–112
*  The relative risk or ratio of means (DHA group vs. control group) is reported as the effect, unless otherwise indicated. Values were adjusted 
for sex, gestational age (<27 weeks or 27 to <29 weeks), and either center (for any intraventricular hemorrhage, sepsis, and length of hospital 
stay) or country (for all other outcomes, owing to the small number of events [<5] at some centers).
†  Excluded were infants who did not have the condition and who died before 36 weeks of postmenstrual age.
‡  Data are for proven necrotizing enterocolitis defined according to the Australian and New Zealand Neonatal Network.21
§  Shown is the duration from birth until the first day that an enteral intake of at least 120 ml per kilogram of body weight per day was reached 
and was subsequently maintained for 3 consecutive days. Infants who did not reach full enteral feeding (29 infants in the DHA group and 
19 in the control group) were excluded.
¶  Shown is the number of days on which one or more feedings were stopped until the assessment of the primary outcome. Missing data, ex‑
cluding deaths and withdrawals, were multiply imputed.
‖  The 88 infants who died were excluded. The treatment effect was calculated with the use of a subdistribution hazard ratio, with death treat‑
ed as a competing risk. A time‑varying coefficient was used for gestational age (<100 days or ≥100 days) to address nonproportionality.
Table 3. Secondary Clinical Outcomes.*
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fer significantly between groups. The significantly 
lower incidence of NICHD-defined mild broncho-
pulmonary dysplasia in the DHA group than in 
the control group reflects a shift to more moder-
ate or severe bronchopulmonary dysplasia in the 
infants who received DHA. We found no evi-
dence of any other adverse effects overall or ac-
cording to subgroup, including inflammatory-
related neonatal illnesses (e.g., intraventricular 
hemorrhage, sepsis, and necrotizing enterocoli-
tis). In contrast to smaller studies showing a de-
creased risk of retinopathy of prematurity asso-
ciated with intravenous DHA supplementation,22-24 
our trial showed no such effect.
Our results highlight the importance of con-
ducting adequately powered randomized trials 
to test new interventions.25 Three previous trials 
that provided DHA at an amount estimated to 
meet fetal accretion rates and that examined 
outcomes with respect to bronchopulmonary 
dysplasia7,26 or respiratory support27 were under-
powered for these outcomes. These previous 
trials (designed to determine the effect of DHA 
supplementation on development7,27 and growth 
failure26) showed inconsistent effects, with one 
suggesting a reduction in bronchopulmonary dys-
plasia in infants with a birth weight of less than 
1250 g7,8 and the others no effect on bronchopul-
monary dysplasia26 or the duration of respiratory 
support.27 Our randomized trial was specifically 
designed to determine the effect of DHA on the 
risk of bronchopulmonary dysplasia and, despite 
biologic plausibility, showed no benefit.
We maximized the chance of detecting an 
effect of DHA on bronchopulmonary dysplasia 
with the mode of delivery (enteral emulsion) and 
DHA dose (60 mg per kilogram per day). DHA 
delivery in previous trials was through breast 
milk or formula,7,27,28 and the full DHA dose 
could be achieved only when the infant reached 
full enteral feeding. By using direct enteral sup-
plementation, we ensured that the full DHA dose 
was given independent of the amount of enteral 
feeding and that supplementation was com-
menced within the first days of life.15 We used a 
DHA dose that was estimated to provide the fe-
tal accretion rate of DHA.7,17 In the context of 
background DHA content in breast milk and for-
mula (providing a total of approximately 20 mg 
of DHA per kilogram per day when the infant 
was receiving full enteral feeding), the infants in 
our trial received a dose of DHA similar to that 
in the trial by Moltu et al.26 (approximately 80 mg 
of DHA per kilogram per day when the infant 
was receiving full enteral feeding); this dose was 
slightly higher than that used in other trials.7,27 
The current intervention resulted in blood DHA 
concentrations similar to those in our previous 
trial of DHA supplementation.29
The DHA preparation that we used did not 
include the n−6 fatty acid arachidonic acid, and 
blood levels of arachidonic acid at baseline and 
trial completion were similar to those observed 
in our previous trial.29 There is controversy over 
the need for supplemental arachidonic acid.17,30 
Our earlier trial, which suggested a possible 
benefit of DHA in the prevention of bronchopul-
monary dysplasia in infants with a birth weight 
of less than 1250 g,7,8 also did not include arachi-
donic acid supplementation beyond that natu-
rally occurring in breast milk and available in 
preterm infant formula. Supplementation with 
both DHA and arachidonic acid was used in 
previous trials that showed no significant differ-
ences between infants receiving supplementation 
and the control group with respect to broncho-
pulmonary dysplasia26 or the requirement for 
respiratory support.27
We used a physiological definition of bron-
chopulmonary dysplasia that decreased variation 
in the diagnosis of the disorder among centers,19 
and we assessed the oxygen saturation of infants 
who were not receiving assisted ventilation and 
who were breathing ambient air at the time of 
the primary outcome assessment. Our prespeci-
fied definition of bronchopulmonary dysplasia 
included contemporary practices of supplemen-
tal oxygen that use high-flow devices and air de-
livered by high or low flow. We consider these 
results to be generalizable to preterm infants in 
high-income countries, which use similar treat-
ment strategies. Bronchopulmonary dysplasia is 
difficult to define.2,31 Extremely preterm infants 
can have impaired lung function irrespective of 
a diagnosis of bronchopulmonary dysplasia.32 The 
complexity of defining the disorder highlights the 
difficulty in interpreting the clinical importance 
of our finding of a higher incidence of physio-
logical bronchopulmonary dysplasia in the DHA 
group than in the control group. Longer term 
follow-up is important to assess the extent of 
airway disease in early childhood32,33 as well as 
neurodevelopment.
Intravenous lipid emulsions providing DHA at 
doses similar to those given in our trial are be-
ing used to provide nutritional support during 
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the transition to full enteral feeding in preterm 
infants, although with limited testing in clinical 
trials.34,35 Our results raise questions about the 
safety of this strategy and suggest the need for 
further study.
In conclusion, our results show that an en-
teral emulsion of DHA at a dose of 60 mg per 
kilogram per day did not result in a lower risk of 
bronchopulmonary dysplasia than control and 
may have resulted in a greater risk.
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